Data as of Apr 17
| -0.01 / -0.30%|
The 4 analysts offering 12-month price forecasts for ZIOPHARM Oncology Inc have a median target of 7.50, with a high estimate of 12.00 and a low estimate of 1.00. The median estimate represents a +122.55% increase from the last price of 3.37.
The current consensus among 5 polled investment analysts is to Buy stock in ZIOPHARM Oncology Inc. This rating has held steady since April, when it was upgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.